meropenem + pralurbactam

**Meropenem + pralurbactam** is an investigational combination of **meropenem**, a broad-spectrum carbapenem antibiotic, and **pralurbactam (FL058)**, a novel non-β-lactam diazabicyclo β-lactamase inhibitor. Meropenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, resulting in cell lysis and death. Pralurbactam inhibits class A, C, and D β-lactamases, protecting meropenem from enzymatic degradation and restoring its efficacy against carbapenem-resistant Enterobacterales, particularly strains producing KPC and OXA-48 β-lactamases. The combination is undergoing clinical assessment for the treatment of infections caused by multidrug-resistant Gram-negative bacteria such as Klebsiella pneumoniae and Escherichia coli[1][2]. Preclinical models suggest good safety and pharmacokinetics for pralurbactam and strong synergistic activity against β-lactamase producing organisms[1][2].

Other names

meropenem + pralurbactampralurbactam/meropenem